Formulation protocol:
1. Ahmed MS, Farag AB, Boys IN, Wang P, Menendez-Montes I, Nguyen NUN, Eitson JL, Ohlson MB, Fan W, McDougal MB, Mar K, Thet S, Ortiz F, Kim SY, Solmonson A, Williams NS, Lemoff A, DeBerardinis RJ, Schoggins JW, Sadek HA. FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms. Biomed Pharmacother. 2023 Jun;162:114614. doi: 10.1016/j.biopha.2023.114614. Epub 2023 Mar 28. PMID: 37068330; PMCID: PMC10043961.
2. Majewsky M, Castel D, Le Dret L, Johann P, Jones DT, Pfister SM, Haefeli WE, Burhenne J. Systematic identification of suspected anthelmintic benzimidazole metabolites using LC-MS/MS. J Pharm Biomed Anal. 2018 Mar 20;151:151-158. doi: 10.1016/j.jpba.2017.12.056. Epub 2017 Dec 28. PMID: 29328982.
3. Studenovský M, Rumlerová A, Kovářová J, Dvořáková B, Sivák L, Kostka L, Berdár D, Etrych T, Kovář M. HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In Vivo. Pharmaceutics. 2022 Jun 4;14(6):1201. doi: 10.3390/pharmaceutics14061201. PMID: 35745774; PMCID: PMC9229042.
4. Huang M, Wang C, Yao Y, Li H, Yao Y, Zhu Y, Cui Y, Yuan Y, Sha J. Mebendazole-Induced Blood-Testis Barrier Injury in Mice Testes by Disrupting Microtubules in Addition to Triggering Programmed Cell Death. Int J Mol Sci. 2022 Apr 11;23(8):4220. doi: 10.3390/ijms23084220. PMID: 35457043; PMCID: PMC9029725.
In vitro protocol:
1. Ahmed MS, Farag AB, Boys IN, Wang P, Menendez-Montes I, Nguyen NUN, Eitson JL, Ohlson MB, Fan W, McDougal MB, Mar K, Thet S, Ortiz F, Kim SY, Solmonson A, Williams NS, Lemoff A, DeBerardinis RJ, Schoggins JW, Sadek HA. FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms. Biomed Pharmacother. 2023 Jun;162:114614. doi: 10.1016/j.biopha.2023.114614. Epub 2023 Mar 28. PMID: 37068330; PMCID: PMC10043961.
2. Majewsky M, Castel D, Le Dret L, Johann P, Jones DT, Pfister SM, Haefeli WE, Burhenne J. Systematic identification of suspected anthelmintic benzimidazole metabolites using LC-MS/MS. J Pharm Biomed Anal. 2018 Mar 20;151:151-158. doi: 10.1016/j.jpba.2017.12.056. Epub 2017 Dec 28. PMID: 29328982.
In vivo protocol:
1. Studenovský M, Rumlerová A, Kovářová J, Dvořáková B, Sivák L, Kostka L, Berdár D, Etrych T, Kovář M. HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In Vivo. Pharmaceutics. 2022 Jun 4;14(6):1201. doi: 10.3390/pharmaceutics14061201. PMID: 35745774; PMCID: PMC9229042.
2. Huang M, Wang C, Yao Y, Li H, Yao Y, Zhu Y, Cui Y, Yuan Y, Sha J. Mebendazole-Induced Blood-Testis Barrier Injury in Mice Testes by Disrupting Microtubules in Addition to Triggering Programmed Cell Death. Int J Mol Sci. 2022 Apr 11;23(8):4220. doi: 10.3390/ijms23084220. PMID: 35457043; PMCID: PMC9029725.